




RealRate

PHARMACEUTICAL 2022

Zymeworks Inc.
Rank 324 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Zymeworks Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zymeworks Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Zymeworks Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 159% points.

The company's Economic Capital Ratio, given in the ranking table, is -222%, being 55% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	288,220
Cost of Goods Sold	0
Intangible Assets	15,854
Liabilities, Current	71,853
Liabilities, Non-Current	33,671
Other Assets	62,275
Other Compr. Net Income	0
Other Expenses	-516
Other Liabilities	34,514
Other Net Income	3,274
Property and Equipment	22,783
Research and Development	199,752
Revenues	26,680
Selling, General and Administrative Expense	42,561

Output Variable	Value in 1000 USD
Assets	389,132
Liabilities	140,038
Expenses	241,797
Stockholders Equity	249,094
Net Income	-211,843
Comprehensive Net Income	-211,843
Economic Capital Ratio	-222%